- Home
- BEAM vs RCKT Comparison
BEAM vs RCKT Comparison
Compare BEAM & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- RCKT
- Stock Information
- Founded
- BEAM 2017
- RCKT 1999
- Country
- BEAM United States
- RCKT United States
- Employees
- BEAM N/A
- RCKT N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- BEAM Health Care
- RCKT Health Care
- Exchange
- BEAM Nasdaq
- RCKT Nasdaq
- Market Cap
- BEAM 1.9B
- RCKT 264.0M
- IPO Year
- BEAM 2020
- RCKT N/A
- Fundamental
- Price
- BEAM $19.45
- RCKT $2.81
- Analyst Decision
- BEAM Strong Buy
- RCKT Buy
- Analyst Count
- BEAM 11
- RCKT 13
- Target Price
- BEAM $48.90
- RCKT $18.50
- AVG Volume (30 Days)
- BEAM 2.4M
- RCKT 3.6M
- Earning Date
- BEAM 08-05-2025
- RCKT 08-04-2025
- Dividend Yield
- BEAM N/A
- RCKT N/A
- EPS Growth
- BEAM N/A
- RCKT N/A
- EPS
- BEAM N/A
- RCKT N/A
- Revenue
- BEAM $63,578,000.00
- RCKT N/A
- Revenue This Year
- BEAM N/A
- RCKT N/A
- Revenue Next Year
- BEAM $17.18
- RCKT N/A
- P/E Ratio
- BEAM N/A
- RCKT N/A
- Revenue Growth
- BEAM N/A
- RCKT N/A
- 52 Week Low
- BEAM $13.53
- RCKT $2.19
- 52 Week High
- BEAM $35.25
- RCKT $26.98
- Technical
- Relative Strength Index (RSI)
- BEAM 63.94
- RCKT 41.85
- Support Level
- BEAM $20.75
- RCKT $2.76
- Resistance Level
- BEAM $22.51
- RCKT $3.24
- Average True Range (ATR)
- BEAM 1.18
- RCKT 0.19
- MACD
- BEAM 0.35
- RCKT 0.13
- Stochastic Oscillator
- BEAM 74.58
- RCKT 49.10
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.